The QoL scores indicate that the condition of the patients receiving the protocols was acceptable, considering the severity of their disease. The treatments were reasonably-well tolerated.

The EORTC Quality of Life Group has developed a questionnaire for evaluating Quality of Life in international clinical trials: EORTC QLQ-C30, which is widely used in many countries. The purpose of this study was to assess the psychometric properties of the third version of this questionnaire, EOR-TC QLQ-C30 (version 3.0), when applied to Spanish prostate cancer patients. METHODS: A sample of 137 prostate cancer patients prospectively filled in the questionnaire three times: on the first and last day of the treatment, and in the followup period. Psychometric evaluation of the structure, reliability and validity was made.

Quality of Life in the present sample has been good in general. The treatment has been administered to patients who could tolerate it adequately.

Quality of life scores and clinical data indicate that the situation of the patients who have received the treatments has been good. Patients under treatment stood it adequately.

To assess the quality of life of a sample of lung cancer patients during their treatment. • Material and methods: 170 patients with limited and advanced small-cell lung cancer (SCLC), and with stages III and IV non-small cell lung cancer (NSCLC) were considered. Patients filled the EORTC QLQ-C30 questionnaire, and the EORTC-LC13 lung module at three different times during the treatment and follow-up. Demographic and clinical data were also recorded. We compared the groups according to the stage and treatment modality, and studied the changes of the quality of life throughout time. • Results: The quality of life scores of the patients under the given protocols: were acceptable in the three considered measurements, as were also the toxicity scores. At the base line there are limitations in the areas of symptoms of disease and quality of life. Few differences were observed between the groups at different stages and under the different treatment modalities. The quality of life scores were similar according to the three measurements. Treatment modality showed a specific effect in the second measurement, while in the third one it improved in some toxicity areas and persisted in others. • Conclusions: The quality of life of the patients receiving the complete protocols was acceptable. The patients under treatment stood it adequately.